Healthcare M&A hit $926B in 2021. By 2024 it was $353B. That gap is your window.

The healthcare M&A market had its best year on record in 2021 — 7,628 deals worth $926B globally. By 2024, deal count had fallen to 4,111 and total value to $353B. That's a 46% drop in transaction volume in three years.

But in 2025, something interesting happened. Deal count stayed low (4,345 transactions) — but total value surged back to $878B. That means fewer deals, but bigger checks. Large PE and strategic acquirers are chasing mega-deals. The $10M–$50M healthcare services market is largely being ignored.

What the multiples say

S&P Capital IQ data shows healthcare deals trading at a median TEV/EBITDA of 6.45x (last 12 months). That's a market-wide average — it includes large hospital systems and publicly traded healthcare companies. For the $10M–$50M SMB healthcare space, apply a 20–40% small company discount.

Why this matters for buyers right now

The 18.2% average acquisition premium tells you that sellers in healthcare are getting paid well above pre-deal trading values. That's a competitive dynamic — but it's concentrated at the large-cap end. A $15M clinic group isn't running a competitive process the way a $200M hospital system does.

At the $10M–$30M level, you're buying from owner-operators who are often motivated by retirement, partnership transitions, or the complexity of running a multi-location group. That's a fundamentally different negotiating dynamic — and professional diligence gives you an information advantage that most buyers at this size don't have.

What to look for in healthcare diligence

The specific risks in healthcare services that most buyers miss:

• Payer mix concentration — is the business over-reliant on one insurer or government payer?
• Key physician risk — does the value walk out the door if one doctor leaves?
• Billing practices — are historical revenue numbers clean, or are there compliance risks hiding in the books?
• Regulatory exposure — licenses, accreditation, and compliance history are not always disclosed proactively.
• Working capital cycles — healthcare receivables are slower than most businesses. The working capital peg matters.

This is exactly why combined commercial and financial due diligence — done by someone who understands both the market dynamics and the numbers — changes outcomes at this deal size.